These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35557564)

  • 1. Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.
    Ono A; Murakami Y; Abdel-Wahab M; Nagata Y
    J Gastrointest Oncol; 2022 Apr; 13(2):885-897. PubMed ID: 35557564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
    Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
    Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
    Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
    Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M;
    Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Jung HS; Kim HS; Kang JS; Kang YH; Sohn HJ; Byun Y; Han Y; Yun WG; Cho YJ; Lee M; Kwon W; Jang JY
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
    Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
    Ratnayake CBB; Roberts KJ; Pandanaboyana S
    Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.
    Hajibandeh S; Hajibandeh S; Intrator C; Hassan K; Sehmbhi M; Shah J; Mazumdar E; Kausar A; Satyadas T
    Ann Hepatobiliary Pancreat Surg; 2023 Feb; 27(1):28-39. PubMed ID: 36536501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
    Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
    Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Trial (JASPAC05).
    Takahashi S; Ohno I; Ikeda M; Konishi M; Kobayashi T; Akimoto T; Kojima M; Morinaga S; Toyama H; Shimizu Y; Miyamoto A; Tomikawa M; Takakura N; Takayama W; Hirano S; Otsubo T; Nagino M; Kimura W; Sugimachi K; Uesaka K
    Ann Surg; 2022 Nov; 276(5):e510-e517. PubMed ID: 33065644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
    Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
    World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer.
    He J; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2021 Mar; 28(3):1514-1520. PubMed ID: 33415556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
    Masui T; Nagai K; Anazawa T; Sato A; Uchida Y; Nakano K; Yogo A; Kaneda A; Nakamura N; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Mizumoto M; Seo S; Hata K; Taura K; Kawaguchi Y; Takaori K; Uemoto S; Hatano E
    BMC Cancer; 2022 Jan; 22(1):119. PubMed ID: 35093003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.